Case Report

Tracheal Papilloma Treated with Cryotherapy and Interferon-α: A Case Report and Review of the Literature

Fatma Yıldırım,1 Murat Türk,1 Sedat Demircan,2 Nalan Akyürek,3 and Ahmet Selim Yurdakul1

1Department of Pulmonary Medicine, Gazi University Faculty of Medicine, Ankara, Turkey
2Department of Thoracic Surgery, Gazi University Faculty of Medicine, Ankara, Turkey
3Department of Pathology, Gazi University Faculty of Medicine, Ankara, Turkey

Correspondence should be addressed to Fatma Yıldırım: fatma_bodur2000@yahoo.com

Received 21 December 2014; Revised 11 February 2015; Accepted 11 February 2015

1. Introduction

Tracheal papilloma (TP) is a neoplastic lesion secondary to tracheal manifestation of recurrent respiratory papillomatosis (RRP) and characterized by papillomatous growth of the bronchial epithelium as a response to Human Papilloma Virus (HPV) infection. Recurrent bronchoscopic interventions and adjuvant medical therapy are needed in its management. It should be closely followed up since malign transformation is reported especially in smokers. Here we present a case of solitary tracheal papilloma that underwent bronchoscopic endobronchial therapy and had no recurrence during follow-up under medical therapy.

2. Case

40-year-old, active smoker male presented with progressive shortness of breath for the last three months. He had no other respiratory or systemic symptoms. His physical examination was unremarkable other than decreased lung sounds. Routine blood tests and chest X-ray were normal (Figure 1). At chest computed tomography (CT) a mass was seen at the distal trachea, nearly obstructing the lumen (Figure 2). At fiberoptic bronchoscopic (FOB) evaluation, there was a papillomatous lesion at the posterolateral wall of the distal 1/3 of trachea, causing ~80% obstruction at the lumen (Figure 3). The lesions were extracted under general anesthesia via endobronchial therapy by rigid bronchoscopy (mechanical debridement and cryotherapy).

In the pathology, squamous epithelial hyperplasia of bronchial epithelium with small papillomatous structures was seen (Figure 4). There was perinuclear cytoplasmic vacuolisation (koilocytosis) in some cells at the superficial aspect of the epithelium. There were no dysplastic changes in the epithelial cells (Figure 5). Immunohistochemical studies for determining etiology were positive for HPV. Polymerase chain reaction amplification detected HPV type 6 DNA in the papilloma tissue.

Subcutaneous interferon-2α (IFN-α) treatment was started in doses of 3 million units per square meter 3 times per week. Computed tomography and bronchoscopic evaluation at the 3rd month of the treatment showed no recurrence (Figure 6) and IFN-α treatment was continued for 6 months.
The patient is still under close follow-up at the 8th month of his diagnosis without recurrence.

3. Discussion

Tracheal papilloma (TP) is a rare tumor of trachea consisting of 0.38% of all lung tumors. It can be solitary, multiple, or as a form of recurrent respiratory papillomatosis (RRP). Respiratory papillomatosis is mostly seen in the larynx but it can affect any part of tracheobronchial tree. It is rarely isolated in trachea. Distal tracheal involvement was reported only in the 5% of RRP cases. In a study, TP is reported in only 5 cases of 15,000 bronchoscopies [1–3]. In our patient, the papillomatous lesion was attached to the tracheal wall with a peduncle and there were no other tracheal or endobronchial lesions.

Although RRP can be seen in all ethnic and age groups, the majority of the reported cases are Caucasian and its distribution is bimodal as in childhood and adulthood. The incidence of RRP in childhood is 43/1,000,000, whereas in adults it is 18/1,000,000. Even though it is thought to be related to vertical transmission at vaginal delivery, there are also a small number of cases reported after cesarean section. Etiology of adulthood RRP is unknown, and it is not certain if the disease is due to sexual transmission or the activation of latent infection [4, 5]. Our patient was 40 years old. He had no prior history of RRP in his childhood or HPV history of his mother.

Tracheal papilloma has no specific clinical presentations and has a wide range of symptoms from cough, shortness of breath at rest or with effort to stridor, and upper airway obstruction. Presentation as bronchial hypersensitivity is also reported in the literature. There is no specific finding at physical examination either [6, 7]. Gao and Cao [8] reported a case with TP similar to our case. Tracheal papilloma occupied 90% of tracheal lumen and physical examination showed that there was a third-degree respiratory distress in their case. In our case, the patient had progressive dyspnea.

The role of imaging in differential diagnosis is limited. Tracheal lesions can be seen at chest X-ray, especially at lateral
projection. Chest computed tomography (CT) may identify lesions at trachea and large airways. Fixed or reversible obstruction in the respiratory function tests may aid in diagnosis. The definitive diagnosis is made by FOB and in most cases no other method is needed for diagnosis [9–11]. In our case, tracheal lesion has not been seen on chest X-ray. He was diagnosed by FOB after the lesion was detected at chest CT.

Although TP is known to be benign, there is a very low risk for malign transformation. Malign transformation is more common in HPV-11 than HPV-16 types and its frequency is 0.3–5% [12]. In the follow-up of 244 patients, Naka et al. [2] found the malignity risk as 1.6%. In a study by Barzó et al. [3], carcinoma in situ was detected in 9.4% of 32 patients with laryngeal and tracheal papillomatosis. Xiao et al. [13] reported a case with malign transformation of TP. Reported risk factors that could be related to malign transformation are the radiation exposure, smoking, and bleomycin treatment [14].

Tracheal papilloma treatment is hard and generally requires recurrent endoscopic interventions as well as medical treatment. There are no therapeutic guidelines or randomized study comparing treatment options at this point. Treatment modalities change according to the type, severity, number, and location of the papillomas [15].

In the management of TP, the first aim is to remove the tumor and sustain the airway patency. Since malign degeneration can occur in papillomas, their surgical excision is essential. In RRP, if the lesion is small, segmentectomy can be performed in order to preserve respiratory functions [16]. Various endoscopic surgical methods are successfully used in the management of papillomas. Among these, excision by carbon dioxide laser is most commonly used especially in children [2,17]. Cryotherapy is also reported to be successful in cases with endobronchial obstruction like our case [18]. If the lesions are limited to a small part of the bronchi, photodynamic therapy, yttrium aluminum garnet (YAG), laser vaporisation, and electrocautery (snare) can be adequate in treatment [19]. In the case of solitary endobronchial papilloma reported by Yıldız et al. [20], a small and localised lesion was resected totally with FOB and forceps biopsies. In two cases of endobronchial papilloma reported by Cömert et al. [21], the lesions were resected by electrocautery snare. Komatsu and Takahashi [22] reported a previously treated TP case that was presented with recurrence after five years and was retreated by KTP/Nd-NAG laser. In our case, since the lesion was large and it caused the obstruction of 80% of tracheal lumen, firstly lumen patency was maintained by forceps biopsies with rigid bronchoscopy and excision of residual tissue with cryotherapy followed.

Local recurrence is common in papillomas. Surgical or bronchoscopic excisions of the lesions are usually not adequate in controlling the disease. For this reason, close clinical follow-up of these patients is very important in the post-excision period. Long and Sani [23] reported that adjuvant therapies (intralesional injection of cidofovir, photodynamic therapy, pulsed dye lase, and indole-3-carbinol) were needed.
in 10% of RRP cases. Current indications for adjuvant therapy are the requirement of more than four surgical interventions per year, the dissemination of the disease, and the rapid growth of the lesion causing airway compression [24, 25]. In our patient, because the lesion was large and occupied 80% of the tracheal lumen and there was an obstruction risk of the airway in case of recurrence, interferon-α (IFN-α) treatment was started as adjuvant therapy.

Interferon-α (IFN-α) is a human leucocyte protein produced naturally as a response to viral infections in the body. It is one of the oldest agents used in the treatment of RRP and its mechanism of action is not fully understood. It binds to receptors at the cells and regulates the cellular metabolism, generating antiproliferative and immune-protective effects. In a multicenter study, solely surgical excision and surgical excision together with IFN-α treatment were compared. At the end of the study, regression of the lesions slowed down at the first six months but this effect did not last two years [26]. In a study by Leventhal et al. [27], patients who were treated with IFN-α were reexamined 6 months after the initiation of the treatment. In their study, there was 75% complete response in one-third of the patients and it was declared that IFN-α treatment can be applied for six months for patients who need surgical excision every two or three months. In a prospective study, patients were followed up for 20 years, it was stated that IFN-α treatment was more effective in HPV-6 infection, and there was no adequate response in patients with HPV-11. Also since malignant transformation is more common and mortality is higher in patients with HPV-11, determination of type of HPV is advised after the first sampling [28]. In light of these studies, IFN-α treatment was applied for six months in our case.

In conclusion, TP is a relatively rare disease that should be closely followed up because of its recurrence and malignant transformation. The present case was successfully treated with cryotherapy and IFN-α treatment and his close clinical and bronchoscopical follow-up will continue.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

[1] H. Miura, T. Tsuchida, N. Kawate, C. Konaka, H. Kato, and Y. Ebihara, “Asymptomatic solitary papilloma of the bronchus: review of occurrence in Japan,” European Respiratory Journal, vol. 6, no. 7, pp. 1070–1073, 1993.
[2] Y. Naka, K. Nakao, Y. Hamaji, M. Nakahara, M. Tsujimoto, and K. Nakahara, “Solitary squamous cell papilloma of the trachea,” Annals of Thoracic Surgery, vol. 55, no. 1, pp. 189–193, 1993.
[3] P. Barzó, L. Molnár, and K. Minik, “Solitary squamous cell papilloma of the trachea,” Chest, vol. 92, no. 1, pp. 132–136, 1987.
[4] L. R. Armstrong, C. S. Derkay, and W. C. Reeves, “Initial results from the national registry for juvenile-onset recurrent respiratory papillomatosis. RRP Task Force,” Archives of Otolaryngology—Head and Neck Surgery, vol. 125, no. 7, pp. 743–748, 1999.
[5] J. R. Kosko and C. S. Derkay, “Role of cesarean section in prevention of recurrent respiratory papillomatosis—is there one?" International Journal of Pediatric Otorhinolaryngology, vol. 35, no. 1, pp. 31–38, 1996.
[6] D. P. Breen, O. Lyons, H. Barrett, and C. Burke, “Isolated tracheal papillomatosis—an infrequent cause of chronic cough,” Respiratory Medicine Extra, vol. 3, no. 1, pp. 21–22, 2007.
[7] J. Valentin, C. B. Brane, K. E. Studtmann, and J. M. Manaligod, “Primary tracheal papillomatosis presenting as reactive airway disease,” Otolaryngology—Head and Neck Surgery, vol. 126, no. 1, pp. 79–80, 2002.
[8] Y. Gao and Z. Cao, “A case of tracheal papilloma,” Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, vol. 27, no. 1, p. 51, 2013.
[9] H. H. Dedo and K. C. Y. Yu, “CO2 laser treatment in 244 patients with respiratory papillomas,” Laryngoscope, vol. 111, no. 9, pp. 1639–1644, 2001.
[10] V. V. Sokolov, A. A. Gladyshev, L. V. Teleghina et al., “Combined endolaryngeal videendoscopic surgery and photodynamic treatment of patients with recurrent laryngeal and tracheal papillomatosis,” Vestnik Otorinolaringologii, no. 6, pp. 4–9, 2007.
[11] A. J. Donne, L. Hampson, J. J. Homer, and I. N. Hampson, “The role of HPV type in recurrent respiratory papillomatosis,” International Journal of Pediatric Otorhinolaryngology, vol. 74, no. 1, pp. 7–14, 2010.
[12] H. H. Popper, Y. El-Shabrawi, W. Wöckel et al., “Prognostic importance of human papilloma virus typing in squamous cell papilloma of the bronchus: comparison of in situ hybridization and the polymerase chain reaction,” Human Pathology, vol. 25, no. 11, pp. 1191–1197, 1994.
[13] Y. Xiao, J. Wang, D. Han, and L. Ma, “A case of the intrapulmonary spread of recurrent respiratory papillomatosis with malignant transformation,” American Journal of the Medical Sciences, 2014.
[14] M. Eloise, “Recurrent Respiratory Papillomatosis eMedicine,” http://emedicine.medscape.com/article/302648.
[15] K. Harris and M. Chalhoub, “Tracheal papillomatosis: what do we know so far?” Chronic Respiratory Disease, vol. 8, no. 4, pp. 233–235, 2011.
[16] Y. Inoue, M. Oka, H. Ishii et al., “A solitary bronchial papilloma with malignant changes,” Internal Medicine, vol. 40, no. 1, pp. 56–60, 2001.
[17] P. P. Sjögren and J. D. Sidman, “Use of the carbon dioxide laser for tracheobronchial lesions in children,” JAMA Otolaryngology—Head and Neck Surgery, vol. 139, no. 3, pp. 231–235, 2013.
[18] K. T. Mohan, J. Greenheck, and E. R. Rubio, “Recurring tracheal papillomatosis treated with cryosurgery,” Southern Medical Journal, vol. 101, no. 9, pp. 967–968, 2008.
[19] C. T. Bolliger, T. G. Sutedja, J. Straus, and L. Freitag, “Therapeutic bronchoscopy with immediate effect: laser, electrocautery, argon plasma coagulation and stents,” European Respiratory Journal, vol. 27, no. 6, pp. 1258–1271, 2006.
[20] F. Yıldız, M. Sever, N. Kömüs, E. S. Uçan, and O. Sivrikız, “Endobronchial solitary papilloma,” Turkish Respiratory Journal, vol. 12, no. 4, pp. 165–167, 2011.
[21] S. S. Gömert, E. T. Parmaksız, B. Çağlayan et al., “Typical carcinoid and benign endobronchial tumors treated with interventional bronchoscopic methods,” Eurasian Journal of Pulmonology, vol. 15, no. 1, pp. 39–44, 2013.
[22] T. Komatsu and Y. Takahashi, “Tracheal papilloma with exceptionally longer interval of recurrence,” Asian Journal of Surgery, vol. 30, no. 1, pp. 88–90, 2007.
[23] Y. T. Long and A. Sani, “Recurrent respiratory papillomatosis,” Asian Journal of Surgery, vol. 26, no. 2, pp. 112–116, 2003.
[24] S. Stamatakis, T. P. Nikolopoulos, S. Korres, D. Felevis, A. Tzangaroulakis, and E. Ferekidis, “Juvenile recurrent respiratory papillomatosis: still a mystery disease with difficult management,” *Head and Neck*, vol. 29, no. 2, pp. 155–162, 2007.

[25] C. S. Derkay and B. Wiatrak, “Recurrent respiratory papillomatosis: a review,” *Laryngoscope*, vol. 118, no. 7, pp. 1236–1247, 2008.

[26] G. B. Healy, R. D. Gelber, A. L. Trowbridge, K. M. Grundfast, R. J. Ruben, and K. N. Price, “Treatment of recurrent respiratory papillomatosis with human leukocyte interferon. Results of a multicenter randomized clinical trial,” *The New England Journal of Medicine*, vol. 319, no. 7, pp. 401–407, 1988.

[27] B. G. Leventhal, H. K. Kashima, P. Mounts et al., “Long-term response of recurrent respiratory papillomatosis to treatment with lymphoblastoid interferon alfa-N1,” *The New England Journal of Medicine*, vol. 325, no. 9, pp. 613–617, 1991.

[28] V. Gerein, E. Rastorguev, J. Gerein, P. Jecker, and H. Pfister, “Use of interferon-alpha in recurrent respiratory papillomatosis: 20-year follow-up,” *Annals of Otology, Rhinology and Laryngology*, vol. 114, no. 6, pp. 463–471, 2005.